Objective-Restenosis after percutaneous coronary intervention remains to be a serious medical problem. Although mineralocorticoid receptor (MR) has been implicated as a potential target for treating restenosis, the cellular and molecular mechanisms are largely unknown. This study aims to explore the functions of macrophage MR in neointimal hyperplasia and to delineate the molecular mechanisms. Approach and Results-Myeloid MR knockout (MMRKO) mice and controls were subjected to femoral artery injury. MMRKO reduced intima area and intima/media ratio, Ki67-and BrdU-positive vascular smooth muscle cells, expression of proinflammatory molecules, and macrophage accumulation in injured arteries. MMRKO macrophages migrated less in culture. MMRKO decreased Ki67-and BrdU-positive macrophages in injured arteries. MMRKO macrophages were less Ki67-positive in culture. Conditioned media from MMRKO macrophages induced less migration, Ki67 positivity, and proinflammatory gene expression of vascular smooth muscle cells. After lipopolysaccharide treatment, MMRKO macrophages had decreased p-cFos and p-cJun compared with control macrophages, suggesting suppressed activation of activator protein-1 (AP1). Nuclear factor-κB (NF-κB) pathway was also inhibited by MMRKO, manifested by decreased p-IκB kinase-β and p-IκBα, increased IκBα expression, decreased nuclear translocation of p65 and p50, as welll as decreased phosphorylation and expression of p65. Finally, overexpression of serum-and-glucocorticoid-induciblekinase-1 (SGK1) attenuated the effects of MR deficiency in macrophages. Conclusions-Selective deletion of MR in myeloid cells limits macrophage accumulation and vascular inflammation and, therefore, inhibits neointimal hyperplasia and vascular remodeling. Mechanistically, MR deficiency suppresses migration and proliferation of macrophages and leads to less vascular smooth muscle cell activation. At the molecular level, MR deficiency suppresses macrophage inflammatory response via SGK1-AP1/NF-κB pathways. (Arterioscler Thromb Vasc Biol. 2016;36:874-885.
R estenosis after percutaneous coronary intervention (PCI) is still an important clinical problem that is far from being solved. The rate of restenosis has remained >10% even after the introduction of drug-eluting stents aiming to suppress neointimal proliferation. 1 Furthermore, it is particularly challenging to treat restenosis after placement of drug-eluting stents currently available. 2 New strategies have been developed and new targets have been identified with the expectation to achieve better outcome for treating restenosis.
Although experimental data have identified mineralocorticoid receptor (MR) as a potential target for treating restenosis after PCI, clinical evidence is controversial. Eplerenone, an antagonist of MR, suppresses vascular remodeling after angioplasty of coronary arteries and neointima formation after stent implantation in coronary arteries of swine. 3, 4 However, the effects of MR antagonists on restenosis in human patients are uncertain. Early study has shown that spironolactone, another antagonist of MR, does not change the incidence of restenosis at 6 months after stenting in a clinical trial. 5 More recent results, however, have demonstrated that spironolactone reduces the rate of repeat revascularization at 1 year after PCI. 6 Different population, length of treatments, and end points between the 2 studies may have contributed to the differential results. More fundamental studies on the cellular and molecular mechanisms how MR is involved in restenosis are needed to provide new insights for ultimately using this target to treat restenosis.
Recent studies using knockout mouse models have begun to reveal the cell type-specific influence of MR in the vasculature. 7 MR in monocytes/macrophages may play important roles in neointimal hyperplasia. Myeloid MR knockout (MMRKO) mouse was established and used to study the functions of macrophage MR in the cardiovascular system. The data have illustrated the importance of macrophage MR in cardiac hypertrophy, fibrosis, and inflammation. [8] [9] [10] [11] Much less has been explored in the vasculature using MMRKO mice. Decreased vascular fibrosis and remodeling have been observed in MMRKO mice challenged with N G -nitro-l-arginine methyl ester/angiotensin II or pressure overload. 9, 11 However, these 2 hypertensive models mostly induce remodeling in the adventitia of blood vessels without neointimal formation, and the pathological changes are distinctly different from those during restenosis. Therefore, it has remained unexplored whether macrophage MR is critical in the process of neointimal hyperplasia. Moreover, although MR has been shown to control macrophage polarization and inflammation, 9 little is known about the molecular mechanisms.
In this study, we aim to explore the functions of macrophage MR in neointimal hyperplasia as well as the cellular and molecular mechanisms. We first use a classical femoral wire injury mouse model that resembles the pathological changes after PCI to investigate whether MR deficiency in myeloid cells reduces neointimal hyperplasia and vascular inflammation. Then, we study the cellular mechanisms by evaluating the impacts of MR deletion on migration and proliferation of macrophages, as well as the interactions between macrophages and vascular smooth muscle cells (VSMCs). Finally we further explore the intrinsic molecular signaling pathways that mediate the effects of MR deletion in inflammatory response of macrophages.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Myeloid MR Deficiency Inhibits Arterial Injury-Induced Neointimal Hyperplasia
After wire injury, femoral arteries of MMRKO mice had significantly reduced intima area, intima/media ratio, and thickness of neointima compared with littermate control (LC) mice ( Figure 1A and 1B; Figure IA in the online-only Data Supplement). No difference was detected in the sham-operated arteries between LC and MMRKO mice ( Figure 1A and 1B). Next, we evaluated proliferation of VSMCs by immunofluorescence staining of α-smooth muscle actin (SMA) and Ki67. SMA-positive cells were significantly less in the injured femoral arteries of MMRKO mice ( Figure 1C and 1D). Furthermore, SMA and Ki67 double-positive cells were much less in MMRKO mice, indicating reduced proliferation of VSMCs ( Figure 1C and 1E). Consistently, SMA and BrdU double-positive cells were significantly less in the injured arteries of MMRKO mice ( Figure 1F and 1G ). In addition, MMRKO mice showed less vascular fibrosis measured by picrosirius red staining ( Figure 1H 
Myeloid MR Deficiency Inhibits Arterial Injury-Induced Vascular Inflammation
Quantitative reverse transcription polymerase chain reaction results showed that injured arteries of MMRKO mice had much lower expression of proinflammatory genes, such as interleukin-6 (IL-6), IL-1β, intercellular adhesion molecule-1, macrophage inflammatory protein-1α, macrophage inflammatory protein-1β, macrophage inflammatory protein-2α, inducible nitric oxide synthase, and matrix metallopeptidase-9 ( Figure 2A ). The 2 groups had comparable expression of other genes, including tumor necrosis factor-α, chemokine (C-X-C motif) ligand 1, regulated on activation, normal T-cell expressed and secreted, and cyclooxygenase 2 ( Figure 2A ). Immunohistochemical staining showed markedly attenuated staining of IL-6 and IL-1β in MMRKO mice ( Figure 2B and 2C).
We then examined accumulation of macrophages within femoral arteries by F4/80 and Mac2 immunohistochemical Nonstandard Abbreviations and Acronyms Figure 2B and 2C). Consistently, injured arteries from MMRKO mice had significantly less gene expression of F4/80 and Mac2 ( Figure 2D ). Relative amounts of total Ly6C high and Ly6C low monocytes in the blood were comparable between LC and MMRKO mice after wire injury ( Figure III in the online-only Data Supplement).
Myeloid MR Deficiency Inhibits Macrophage Migration
The diminished macrophage accumulation in the vascular wall of MMRKO mice responding to wire injury could be attributable to at least 2 events, less migration of monocytes and less proliferation of macrophages. We first investigated the possibility of reduced migration of monocytes/ macrophages. Migration of monocytes/macrophages is determined by 2 aspects, the amount of stimulating factors and the migratory ability of monocytes/macrophages responding to these factors. Cytokines such as monocyte chemoattractant protein-1 (MCP1) and osteopontin are known to play essential roles in macrophage migration. [12] [13] [14] Gene expression of MCP1 and its receptors, chemokine (C-C motif) receptor 2 and chemokine (C-C motif) receptor 4, as well as osteopontin was much lower in the injured arteries of MMRKO mice ( Figure 3A ). Immunohistochemical staining of MCP1 and osteopontin showed that protein levels of these cytokines were also markedly reduced ( Figure 3B and 3C) .
Transwell assay displayed that the migratory ability of peritoneal macrophages from MMRKO mice was markedly inhibited both at baseline and when stimulated by either MCP1 (Figure 3D and 3E) or osteopontin ( Figure 3F and 3G). Gene expression of MCP1 and osteopontin in peritoneal macrophages showed no difference between LC and MMRKO ( Figure IV in the online-only Data Supplement), suggesting that the difference observed in femoral arteries was not from macrophages. However, gene expression of chemokine (C-C motif) receptor 2 and chemokine (C-C motif) receptor 4 was significantly suppressed in MMRKO macrophages ( Figure 3H ), further supporting the impaired migratory ability of these macrophages.
Taken together, MMRKO decreased migration of monocytes/macrophages probably by reducing the amount of cytokines in the vascular wall after injury and suppressing the migratory ability of macrophages.
Myeloid MR Deficiency Inhibits Macrophage Proliferation
We then addressed the second possibility that MMRKO decreased proliferation of macrophages. Mac2-positive cells were significantly decreased in the injured arteries of MMRKO mice compared with LC mice ( Figure 4A and 4B). Interestingly, Mac2 and Ki67 double-positive cells were readily detected in the injured arteries, indicating the existence of proliferative macrophages in this model ( Figure 4A and 4C). Furthermore, the double-positive cells were much less in MMRKO mice, suggesting reduced proliferation of macrophages ( Figure 4A Proliferation of macrophages is also determined by 2 aspects, the amount of stimulating factors and the proliferative ability of macrophages responding to these factors. Macrophage colony-stimulating factor (M-CSF) and IL-4 are the 2 important factors that promote macrophage proliferation. 15, 16 Interestingly, gene expression of M-CSF, but not IL-4, was markedly lower in the injured arteries of MMRKO mice ( Figure 4F ; Figure VIIA in the online-only Data Supplement).
Peritoneal macrophages from MMRKO mice had decreased gene expression of CSF-1R, the receptor of M-CSF ( Figure  4G ), implicating reduced proliferative ability of MR-deficient macrophages. We then assessed proliferation of macrophages responding to L929-conditioned media (CM) in which M-CSF is the major stimulator. Mac2 and Ki67 staining showed that peritoneal macrophages from MMRKO mice had significantly less proliferation with or without L929 CM stimulation ( Figure  4H and 4I) . Consistently, MRKO macrophages had decreased protein expression of proliferating cell nuclear antigen and increased protein expression of P27 ( Figure 4J and 4K ). Gene expression of M-CSF in peritoneal macrophages showed no difference between LC and MMRKO ( Figure VIIB in the onlineonly Data Supplement), suggesting that the difference observed in femoral arteries was not from macrophages.
These data together demonstrated that MMRKO inhibited macrophage proliferation probably through reducing the availability of M-CSF in the microenvironment of injured arteries and downregulating the proliferative ability of macrophages.
Conditioned Media From MR-Deficient Macrophages Induce Less Migration, Proliferation, and Proinflammatory Gene Expression of VSMCs
VSMC migration, proliferation, and cytokine production are crucial pathophysiological processes in restenosis. 17 CM were collected from LC or MRKO macrophages treated without lipopolysaccharide (LPS; designated as CM) or with LPS (designated as LPS CM) and used to stimulate mouse primary VSMCs. Transwell assay showed that LPS CM derived from MRKO macrophages induced markedly less migration of VSMCs than those from LC macrophages ( Figure 5A and 5B) . Similarly, much less Ki67-positive VSMCs were observed in the group treated with LPS CM derived from MRKO macrophages ( Figure 5C and 5D ). In addition, VSMCs treated with LPS CM from MRKO macrophages had much lower expression of proinflammatory genes, such as IL-6, IL-1β, regulated on activation, normal T-cell expressed and secreted, and vascular cell adhesion molecule-1 ( Figure 5E ). Expression of other proinflammatory genes was not significantly different between the 2 groups ( Figure VIIIA in the online-only Data Supplement).
The concentrations of LPS in LPS CM from LC and MRKO macrophages were similar ( Figure VIIIB in the onlineonly Data Supplement), suggesting that the different impacts on VSMCs were not likely because of LPS. Instead, the difference may be attributable to the much lower levels of IL-6 and IL-1β in LPS CM from MRKO macrophages ( Figure VIIIC in the online-only Data Supplement). Gene expression of IL-6 and IL-1β was among the most dramatically increased responding to LPS and suppressed in MRKO macrophages ( Figure VIIID in the online-only Data Supplement). When neutralizing antibody against IL-6 and that against IL-1β were added together, the different impacts of LPS CM derived from LC and MRKO macrophages on migration, proliferation, and inflammatory gene expression of VSMCs were abolished, further supporting that IL-6 and IL-1β mediated the effects of MRKO ( Figure 5A-5E ).
MR Deficiency Impairs AP1 and NF-κB Signaling Pathways in Macrophages
We next explored whether MRKO affected the intrinsic pathways that control the release of proinflammatory cytokines, such as IL-6 and IL-1β in macrophages. LC or MRKO macrophages were treated with LPS and activation of activator protein 1 (AP1), and nuclear factor-κB (NF-κB) pathways were detected. LPS-induced phosphorylation of both c-Fos and c-Jun, components of AP1, was significantly lower in peritoneal macrophages from MMRKO mice compared with those from LC mice ( Figure 6A-6C) . These results suggested that MRKO suppressed AP1 activation in macrophages.
The upstream IκB kinase β was much less phosphorylated in MRKO macrophages after LPS treatment ( Figure 6D and  6E) . Consistently, phosphorylation of IκBα was suppressed in MRKO macrophages while total protein level of IκBα was increased in comparison with LC macrophages (Figure 6D and  6F ). Furthermore, markedly less nuclear p65-positive cells were observed in MRKO macrophages after LPS stimulation ( Figure  6G and 6H) . Similarly, MRKO also inhibited nuclear translocation of NF-κB p50 ( Figure IX in the online-only Data Supplement). In addition, both p-p65 and total p65 were attenuated in MRKO macrophages (Figure 6I, 6J, and 6K) . These results together suggested that MRKO inhibited NF-κB activation in macrophages.
MR Deficiency Suppresses Inflammatory Response and AP1 and NF-κB Signaling Pathways via SGK1 in Macrophages
Previous studies have demonstrated that serum-and-glucocorticoid-inducible-kinase (SGK1), a classical target gene of MR, plays crucial roles in vascular remodeling and regulates inflammatory response in monocytes/macrophages via NF-κB. [18] [19] [20] Our results demonstrated that SGK1 deficiency largely recapitulated the phenotypes of MRKO in macrophages ( Figure X in the online-only Data Supplement).
We therefore hypothesized that SGK1 mediated the effects of MRKO. MRKO markedly reduced gene expression, protein expression, and phosphorylation of SGK1 ( Figure 7A-7C ). Next, we addressed whether SGK1 mediated the effects of MR using Raw264.7 cells with knockdown of MR and overexpression of constitutively active mutant SGK1 (S422D, SGK1-OV; Figure XI in the online-only Data Supplement). MR siRNA markedly suppressed expression of proinflammatory genes such as IL-6 and IL-1β in Raw264.7 cells treated with LPS and SGK1-OV noticeably blunted such suppression ( Figure 7D ). Furthermore, the suppressive effects of MR siRNA on AP1 signaling was attenuated by SGK1-OV ( Figure 7E and 7F) . Similarly, MR siRNA suppressed NF-κB signaling and such effects were either blocked or inhibited by SGK1-OV ( Figure 7G-7J ). SGK1-OV alone had the opposite 
Discussion
MR is an important drug target in the cardiovascular system. 7, 21 Its antagonists (spironolactone and eplerenone) are part of the standard therapeutic regimen for treating heart failure in clinical practice. 22 Although animal studies have shown promising data that these antagonists may be beneficial for restenosis after PCI, they have not been clinically proved. Using a femoral artery wire injury model, in which the endothelial layer is severely damaged along with medial injury and intense mechanical stretching, we demonstrated that MR deficiency in macrophages effectively suppressed neointimal hyperplasia, vascular inflammation, migration and proliferation of monocytes/macrophages. Under inflammatory stimulation, MR-deficient macrophages produced less IL-1β and IL-6 and caused less activation of VSMCs. Intrinsically, MR deficiency led to downregulation of AP1 and NF-κB pathways dependent of SGK1.
We have previously demonstrated the protective roles of macrophage MR deficiency in hypertensive vascular remodeling. 9, 11 This study revealed that blockade of MR in macrophages was sufficient to attenuate wire injury-induced neointimal hyperplasia effectively. This indicates that macrophage MR plays an essential role in the process of restenosis after PCI. It is conceivable to treat restenosis by selectively blockade of MR in monocytes/macrophages using delivery vehicles, such as liposomes or β1,3-d-glucan. 23, 24 These approaches may decrease the side effects of MR blockers, and high dosage becomes feasible for targeting monocytes/macrophages specifically.
MR deficiency affected macrophages in multiple ways. First, we discovered that macrophage proliferation occurred within the vascular wall in the process of neointimal hyperplasia and that MRKO dramatically suppressed the proliferation. The origin of macrophages in the context of inflammation has previously been attributed to recruitment of blood monocytes. 25 However, recent studies have indicated that macrophage proliferation also plays critical roles under inflammatory conditions, such as atherosclerosis and obesity. 26, 27 We used 2 different approaches to show the presence of proliferative macrophages in wire-injured blood vessels. Furthermore, MRKO inhibited the proliferation of macrophages both in vivo and in vitro. Second, MRKO markedly suppressed the migration of monocytes/macrophages. The reduced macrophage accumulation in the vascular wall of MMRKO mice after wire injury is likely attributable to both decreased migration of monocytes and attenuated proliferation of macrophages. However, which event contributes more significantly and whether the proliferated macrophages are initially originated from circulating monocytes remain to be further interrogated. Third, MRKO macrophages produced less proinflammatory cytokines such as IL-1β and IL-6 that, in turn, mediated the activation of VSMCs. Earlier study has shown that conditioned media from aldosterone-stimulated VSMCs promote monocyte chemotaxis in an MR-dependent manner. 28 Therefore, MR mediates the crosstalk between macrophages and VSMCs.
We identified SGK1-AP1/NF-κB pathways as the underlying molecular mechanisms through which MR regulated the inflammatory response of macrophages. Previously, spironolactone has been reported to decrease the DNA-binding activity of AP1 and NF-κB, as well as gene expression of c-Fos in cardiac tissues of renin and angiotensinogen double transgenic rats that overproduce angiotensin II. 29 In spontaneously hypertensive rats, eplerenone decreases aortic expression of IL-1β, IL-6, and tumor necrosis factor-α as well as plasma levels of IL-1β and IL-6, likely through upregulation of IκB expression and downregulation of NF-κB expression. 30 In renal collecting duct cells, aldosterone works through an MR-SGK1/NF-κB pathway to promote expression of NF-κB target genes, including IL-1β and IL-6. 31 Similar pathway has been reported in mesangial cells. 32 However, the molecular mechanisms how MR regulates inflammation in macrophages had been little explored. Our data specifically showed that MR deficiency in macrophages diminished activation of both AP1 and NF-κB in these cells and these effects were dependent on SGK1. A recent study has demonstrated that SGK1 deficiency suppresses NF-κB through inhibition of p-IKK, p-IκB, and P50 nuclear translocation in macrophages and that constitutively active SGK1 conversely activates NF-κB. 20 Our results further demonstrated that SGK1 deficiency in macrophages suppressed LPS-induced proinflammatory gene expression and that both AP1 and NF-κB pathways were downregulated. Therefore, MR deficiency suppresses inflammation in macrophages by downregulation of SGK1, which in turn controls the activation of AP1 and NF-κB that both govern the expression of inflammatory genes, such as IL-1β and IL-6.
Together our data have revealed MR in macrophages as a critical player in neointimal hyperplasia in response to vascular injury and have delineated the intrinsic mechanisms how MR regulates inflammatory response in macrophages. These data have provided new insights on how to target monocytes/macrophages to curb inflammation that is the propelling engine of neointimal hyperplasia in the process of restenosis.
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